2. Epigenetics
  3. Glycosyltransferase

Glycosyltransferase

Glycosyltransferases (GTs) are key enzymes in the biosynthesis of ginsenosides, which can catalyze the transfer of glycans from donor molecules to acceptor molecules, and form a variety of biologically active glycoside compounds.

Glycosyltransferase Related Products (20):

Cat. No. Product Name Effect Purity
  • HY-116705
    2-Deoxy-2-fluoro-L-fucose
    2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma[1].
  • HY-139056
    SU0268 Inhibitor 99.96%
    SU0268 is a potent and specific inhibitor of 8-Oxoguanine DNA glycosylase 1 (OGG1). SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection[1][2][3].
  • HY-107366
    SGN-2FF Inhibitor
    SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity[1].
  • HY-W096600
    2F-Peracetyl-Fucose Inhibitor
    2F-Peracetyl-Fucose (1,3,4-Tri-O-acetyl-2-deoxy-2-fluoro-L-fucopyranos) acts as a potent fucosyltransferase (FUT) inhibitor[1].
  • HY-129389
    Benzyl-α-GalNAc Inhibitor
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-FU (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation[1][2][3].
  • HY-163121
    PST3.1a Inhibitor
    PST3.1a is a N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with the IC50 of 2 μM. PST3.1a inhibits glioblastoma-initiating cell invasiveness and proliferation[1].
  • HY-170663
    β-1,4-GALT1-IN-1 Inhibitor
    β-1,4-GALT1-IN-1 (Compound 6) is a β-1,4-GALT1 inhibitor, with an IC50 value of 6.2 μM. β-1,4-GALT1-IN-1 can be used in many pathology investigations such as cancer, autoimmune diseases and viral infections[1].
  • HY-E70287
    ST6 Sialyltransferase 5
    ST6 Sialyltransferase 5 (EC:2.4.3.3, ST6GALNAC5, SIAT7E, ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5) transfers a sialic acid to N-acetylgalactosamine (GalNAc) residues. ST6 Sialyltransferase 5 is a bio-marker in cervical screening samples[1][2].
  • HY-120872
    AJS1669 free acid Activator 99.15%
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
  • HY-E70160
    Protein O-Fucosyltransferase 1
    Protein O-Fucosyltransferase 1 (EC:2.4.1.221; POFUT1) is a Glycosyltransferase containing the cysteine-rich motifs as the acceptor sugar and GDP-fucose as the donor[1].
  • HY-E70191
    β-1,4-Galactosyltransferase 2
    β-1,4-Galactosyltransferase 2 catal exclusive specificity for the donor substrate UDP-galactose and all transfer galactosein a beta1,4 linkage[1].
  • HY-157461
    Glycation-IN-1
    Glycation-IN-1 (Compound 3) is an inhibitor of glycosylation reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases[1].
  • HY-E70047
    alpha-1,4-Galactosyltransferase (LgtC)
    alpha-1,4-Galactosyltransferase (LgtC) (A4GALT) is a glycosphingolipid-specific glycosyltransferase. alpha-1,4-Galactosyltransferase (LgtC) transfers a galactose to the alpha-1,4 position of lactosylceramide to form globotriaosylceramide. alpha-1,4-Galactosyltransferase (LgtC) can be used for the synthesis of P1 blood group antigens[1][2].
  • HY-169084
    ST-IN-1 Inhibitor
    ST-IN-1 (compound (R)-1) is a selective ST inhibitor (Ki=70 nM, rat a-2,6-ST; Ki=19 nM, hST6GAL1) with antitumor activity. ST-IN-1 inhibits tumor growth and metastasis by delipidating the surface of tumor cells[1].
  • HY-E70141
    β-1,3-N-Acetylglucosaminyltransferase 4
    β-1,3-N-Acetylglucosaminyltransferase 4 (EC:2.4.1.149, B3GNT4) is involved in the synthesis of poly-N-acetyllactosamine and has activity for type 2 oligosaccharides[1].
  • HY-147960
    Glycosyltransferase-IN-1 Inhibitor
    Glycosyltransferase-IN-1 (compound 5m) is a potent glycosyltransferase inhibitor, with an IC50 of 82.8 μM. Glycosyltransferase-IN-1 shows antibacterial activity, with MIC values of 6 μg/mL for MSSA, MRSA, B. subtilis and 12 μg/mL for E. coli[1].
  • HY-E70138
    β-1,4-Galactosyltransferase 7
    β-1,4-Galactosyltransferase 7 has exclusive specificity for the donor substrate UDP-galactose and all transfer galactose in a β-1,4 linkage to similar acceptor sugars: GlcNAc, Glc, and Xyl.[1].
  • HY-E70154
    Fucosyltransferase 3
    Fucosyltransferase 3 (EC:2.4.1.65, FUT3, FT3B) has strong alpha 1-3 and alpha 1-4 fucosyltransferase activities[1].
  • HY-E70044
    beta-1, 3-N-Acetylhexaminyltransferase (LgtA)
    beta-1, 3-N-Acetylhexaminyltransferase (LgtA) is a glycosyltransferase, is often used in biochemical studies. beta-1, 3-N-Acetylhexaminyltransferase (LgtA) catalyzes the transfer of N-acetylglucosamine from UDP-GlcNAc to N-acetyllactosamine and lactose[1].
  • HY-E70159
    Fucosyltransferase 11
    Fucosyltransferase 11 (EC:2.4.1.-, FUT11) links alpha-l-fucose onto conalbumin glycopeptides and biantennary N-glycan acceptors. Fucosyltransferase 11 plays an important role in cancer[1].